J 2020

The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma

GURÍN, Dominik, Marek SLÁVIK, Markéta HERMANOVÁ, Iveta SELINGEROVÁ, Tomáš KAZDA et. al.

Základní údaje

Originální název

The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma

Autoři

GURÍN, Dominik (203 Česká republika, garant, domácí), Marek SLÁVIK (703 Slovensko, domácí), Markéta HERMANOVÁ (203 Česká republika, domácí), Iveta SELINGEROVÁ (203 Česká republika), Tomáš KAZDA (203 Česká republika, domácí), Michal HENDRYCH (203 Česká republika, domácí), Tetiana SHATOKHINA (804 Ukrajina, domácí) a Marcela VESELÁ (203 Česká republika)

Vydání

JOURNAL OF ORAL PATHOLOGY & MEDICINE, HOBOKEN, WILEY, 2020, 0904-2512

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.253

Kód RIV

RIV/00216224:14110/20:00116131

Organizační jednotka

Lékařská fakulta

UT WoS

000544754600001

Klíčová slova anglicky

CD8; HPV; oropharyngeal squamous cell carcinoma; PD-L1; tumor-infiltrating lymphocytes

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 29. 10. 2020 13:38, Mgr. Tereza Miškechová

Anotace

V originále

Background We examined PD-L1 expression on tumor cells (TCs) and immune cells (ICs) and density of CD3(+)and CD8(+)tumor-infiltrating lymphocytes (TILs) in patients with oropharyngeal squamous cell carcinoma (OPSCC) and investigated their significance on clinicopathological characteristics and clinical outcomes. Methods In a cohort of 65 patients treated by definitive intensity-modulated radiotherapy (IMRT) with curative intent, immunohistochemical analysis of PD-L1 expression on TCs and ICs, and TIL subtyping was performed on primary biopsy tumor tissues, followed by prognostic evaluation of these immune response-related parameters including classification into four tumor immune microenvironment (TIM) types. To evaluate HPV status, p16 immunohistochemistry was performed. Results Densities of CD3(+)and CD8(+)TILs and PD-L1 expressions on TCs and ICs were significantly higher in p16+/HPV-mediated OPSCC. Patients with high densities of stromal CD8(+)TILs displayed significantly better overall survival (OS) and progression-free survival (PFS). PD-L1 expression neither on tumor cells nor on immune cells affected survival outcomes. Distribution of TIM types based on the combination of PD-L1 expression on TCs and densities of CD8(+)TILs is significantly different in p16+ compared with p16- OPSCC. In type III TIM (TC-PD-L1+/low CD8(+)TIL density), significantly better OS was shown in p16+ group compared with p16- OPSCC. Conclusion The prognostic and predictive role of tumor immune microenvironment was confirmed for patients with OPSCC. Combining HPV status with the evaluation of densities of CD8(+)TILs and PD-L1 expression including TIM classification might be of high clinical interest and warrants further prospective evaluation.